354 related articles for article (PubMed ID: 23277474)
21. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
Fredj S; Sampson KJ; Liu H; Kass RS
Br J Pharmacol; 2006 May; 148(1):16-24. PubMed ID: 16520744
[TBL] [Abstract][Full Text] [Related]
22. Exploring mutation specific beta blocker pharmacology of the pathogenic late sodium channel current from patient-specific pluripotent stem cell myocytes derived from long QT syndrome mutation carriers.
Comollo TW; Zou X; Zhang C; Kesters D; Hof T; Sampson KJ; Kass RS
Channels (Austin); 2022 Dec; 16(1):173-184. PubMed ID: 35949058
[TBL] [Abstract][Full Text] [Related]
23. Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3.
Ruan Y; Denegri M; Liu N; Bachetti T; Seregni M; Morotti S; Severi S; Napolitano C; Priori SG
Circ Res; 2010 Apr; 106(8):1374-83. PubMed ID: 20339117
[TBL] [Abstract][Full Text] [Related]
24. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.
Matsa E; Rajamohan D; Dick E; Young L; Mellor I; Staniforth A; Denning C
Eur Heart J; 2011 Apr; 32(8):952-62. PubMed ID: 21367833
[TBL] [Abstract][Full Text] [Related]
25. Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.
Hu RM; Tester DJ; Li R; Sun T; Peterson BZ; Ackerman MJ; Makielski JC; Tan BH
Channels (Austin); 2018; 12(1):176-186. PubMed ID: 29983085
[TBL] [Abstract][Full Text] [Related]
26. A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine.
Valdivia CR; Ackerman MJ; Tester DJ; Wada T; McCormack J; Ye B; Makielski JC
Cardiovasc Res; 2002 Aug; 55(2):279-89. PubMed ID: 12123767
[TBL] [Abstract][Full Text] [Related]
27. Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome.
Priori SG; Napolitano C; Cantù F; Brown AM; Schwartz PJ
Circ Res; 1996 Jun; 78(6):1009-15. PubMed ID: 8635231
[TBL] [Abstract][Full Text] [Related]
28. A distinct molecular mechanism by which phenytoin rescues a novel long QT 3 variant.
Gando I; Campana C; Tan RB; Cecchin F; Sobie EA; Coetzee WA
J Mol Cell Cardiol; 2020 Jul; 144():1-11. PubMed ID: 32339567
[TBL] [Abstract][Full Text] [Related]
29. Molecular biology of the long QT syndrome: impact on management.
Priori SG; Napolitano C; Paganini V; Cantù F; Schwartz PJ
Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 2):2052-7. PubMed ID: 9272507
[TBL] [Abstract][Full Text] [Related]
30. Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene.
Carrasco JI; Izquierdo I; Medina P; Arnau MÁ; Salvador A; Zorio E
Rev Esp Cardiol (Engl Ed); 2012 Nov; 65(11):1058-9. PubMed ID: 22721569
[No Abstract] [Full Text] [Related]
31. Electromechanical window negativity in genotyped long-QT syndrome patients: relation to arrhythmia risk.
ter Bekke RM; Haugaa KH; van den Wijngaard A; Bos JM; Ackerman MJ; Edvardsen T; Volders PG
Eur Heart J; 2015 Jan; 36(3):179-86. PubMed ID: 25205533
[TBL] [Abstract][Full Text] [Related]
32. Translation reinitiation in c.453delC frameshift mutation of KCNH2 producing functional hERG K+ channels with mild dominant negative effect in the heterozygote patient-derived iPSC cardiomyocytes.
Park NK; Park SJ; Park YG; Moon SH; Woo J; Kim HJ; Kim SJ; Choi SW
Hum Mol Genet; 2024 Jan; 33(2):110-121. PubMed ID: 37769355
[TBL] [Abstract][Full Text] [Related]
33. Promise and Potential Peril With Lumacaftor for the Trafficking Defective Type 2 Long-QT Syndrome-Causative Variants, p.G604S, p.N633S, and p.R685P, Using Patient-Specific Re-Engineered Cardiomyocytes.
O'Hare BJ; John Kim CS; Hamrick SK; Ye D; Tester DJ; Ackerman MJ
Circ Genom Precis Med; 2020 Oct; 13(5):466-475. PubMed ID: 32940533
[TBL] [Abstract][Full Text] [Related]
34. Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
Cashman JR; Ryan D; McKeithan WL; Okolotowicz K; Gomez-Galeno J; Johnson M; Sampson KJ; Kass RS; Pezhouman A; Karagueuzian HS; Mercola M
J Med Chem; 2021 May; 64(9):5384-5403. PubMed ID: 33942619
[TBL] [Abstract][Full Text] [Related]
35. A novel LQT-3 mutation disrupts an inactivation gate complex with distinct rate-dependent phenotypic consequences.
Bankston JR; Sampson KJ; Kateriya S; Glaaser IW; Malito DL; Chung WK; Kass RS
Channels (Austin); 2007; 1(4):273-80. PubMed ID: 18708744
[TBL] [Abstract][Full Text] [Related]
36. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes.
Viswanathan PC; Bezzina CR; George AL; Roden DM; Wilde AA; Balser JR
Circulation; 2001 Sep; 104(10):1200-5. PubMed ID: 11535580
[TBL] [Abstract][Full Text] [Related]
37. Cardiac channelopathies associated with infantile fatal ventricular arrhythmias: from the cradle to the bench.
Kato K; Makiyama T; Wu J; Ding WG; Kimura H; Naiki N; Ohno S; Itoh H; Nakanishi T; Matsuura H; Horie M
J Cardiovasc Electrophysiol; 2014 Jan; 25(1):66-73. PubMed ID: 24112685
[TBL] [Abstract][Full Text] [Related]
38. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients.
Ruan Y; Liu N; Bloise R; Napolitano C; Priori SG
Circulation; 2007 Sep; 116(10):1137-44. PubMed ID: 17698727
[TBL] [Abstract][Full Text] [Related]
39. 18β-Glycyrrhetinic acid preferentially blocks late Na current generated by ΔKPQ Nav1.5 channels.
Du YM; Xia CK; Zhao N; Dong Q; Lei M; Xia JH
Acta Pharmacol Sin; 2012 Jun; 33(6):752-60. PubMed ID: 22609834
[TBL] [Abstract][Full Text] [Related]
40. Investigation of ion channel gene variants in patients with long QT syndrome.
Ernesto C; Cruz FE; Lima FS; Coutinho JL; Silva R; Urményi TP; Carvalho AC; Rondinelli E
Arq Bras Cardiol; 2011 Mar; 96(3):172-8. PubMed ID: 21308345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
